{"title":"抗菌药物与化疗科学会议-第50届年会-有前景的新药研究:第1部分。","authors":"Karen Walker","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The 50th annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), held in Boston, included topics covering new therapeutic developments in the field of infectious disease. This conference report highlights selected presentations on research with novel antimicrobial agents. Investigational drugs discussed include the dicationic porphyrin derivative XF-73 (Destiny Pharma), the tetracycline analog TP-434 (Tetraphase Pharmaceuticals), an elongation factor Tu inhibitor (Novartis Institutes for BioMedical Research), the dihydrofolate reductase inhibitor Rx-101005 (Trius Therapeutics), SII RMab, a fully human mAb to rabies glycoprotein (Massachusetts Biologic Laboratories/Serum Institute of India), the oral lipopeptide CB-183315 (Cubist Pharmaceuticals) for the treatment of Clostridium difficile-associated diarrhea, the phosphatidylcholine-specific phospholipase C (PC-PLC) inhibitor LMV-601 (Lumavita), and DS-003 (International Partnership for Microbicides), a small-molecule Gp120 inhibitor.</p>","PeriodicalId":55031,"journal":{"name":"Idrugs","volume":"13 11","pages":"743-5"},"PeriodicalIF":0.0000,"publicationDate":"2010-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Interscience Conference on Antimicrobial Agents and Chemotherapy - 50th Annual Meeting - Research on Promising New Agents: Part 1.\",\"authors\":\"Karen Walker\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The 50th annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), held in Boston, included topics covering new therapeutic developments in the field of infectious disease. This conference report highlights selected presentations on research with novel antimicrobial agents. Investigational drugs discussed include the dicationic porphyrin derivative XF-73 (Destiny Pharma), the tetracycline analog TP-434 (Tetraphase Pharmaceuticals), an elongation factor Tu inhibitor (Novartis Institutes for BioMedical Research), the dihydrofolate reductase inhibitor Rx-101005 (Trius Therapeutics), SII RMab, a fully human mAb to rabies glycoprotein (Massachusetts Biologic Laboratories/Serum Institute of India), the oral lipopeptide CB-183315 (Cubist Pharmaceuticals) for the treatment of Clostridium difficile-associated diarrhea, the phosphatidylcholine-specific phospholipase C (PC-PLC) inhibitor LMV-601 (Lumavita), and DS-003 (International Partnership for Microbicides), a small-molecule Gp120 inhibitor.</p>\",\"PeriodicalId\":55031,\"journal\":{\"name\":\"Idrugs\",\"volume\":\"13 11\",\"pages\":\"743-5\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2010-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Idrugs\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Idrugs","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Interscience Conference on Antimicrobial Agents and Chemotherapy - 50th Annual Meeting - Research on Promising New Agents: Part 1.
The 50th annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), held in Boston, included topics covering new therapeutic developments in the field of infectious disease. This conference report highlights selected presentations on research with novel antimicrobial agents. Investigational drugs discussed include the dicationic porphyrin derivative XF-73 (Destiny Pharma), the tetracycline analog TP-434 (Tetraphase Pharmaceuticals), an elongation factor Tu inhibitor (Novartis Institutes for BioMedical Research), the dihydrofolate reductase inhibitor Rx-101005 (Trius Therapeutics), SII RMab, a fully human mAb to rabies glycoprotein (Massachusetts Biologic Laboratories/Serum Institute of India), the oral lipopeptide CB-183315 (Cubist Pharmaceuticals) for the treatment of Clostridium difficile-associated diarrhea, the phosphatidylcholine-specific phospholipase C (PC-PLC) inhibitor LMV-601 (Lumavita), and DS-003 (International Partnership for Microbicides), a small-molecule Gp120 inhibitor.
分享
京公网安备 11010802042870号
京ICP备2023020795号-1
求助内容：
应助结果提醒方式：
扫码关注我们
